Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.

When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.

Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.